Non-biotinylated GLP-1R His&Avi Tag, Human

The GLP-1R (Glucagon-Like Peptide-1 Receptor) belongs to class B G protein-coupled receptors, comprising an N-terminal extracellular domain (ECD), seven-transmembrane helix bundle, and intracellular C-terminus. Upon binding of peptide ligands to the ECD, the receptor ECD dissociates from the transmembrane domain, TM6 and TM7 undergo significant outward displacement, and the G protein α subunit inserts into the receptor core to form a complete signaling complex. This receptor is widely expressed in pancreatic β cells, central nervous system (hypothalamus and brainstem nucleus tractus solitarius), cardiovascular system, and gastrointestinal tract. It promotes glucose-dependent insulin secretion and inhibits glucagon release through the Gs protein-cAMP-PKA pathway, while regulating appetite and energy metabolism via the brain-gut axis. Clinically, GLP-1R agonists such as semaglutide and tirzepatide (a dual GLP-1/GIP receptor agonist) not only significantly reduce HbA1c and cardiovascular event risk in type 2 diabetes patients but also achieve 15%-20% weight loss in obesity treatment. Their therapeutic applications have expanded to MASH (metabolic dysfunction-associated steatohepatitis) and Parkinson's disease, representing a major breakthrough in precision intervention for metabolic diseases.